{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:41:47Z","timestamp":1779896507564,"version":"3.53.1"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Growing primary breast cancers (PT) can initiate local recurrences (LR), regional lymph nodes (pLN) and distant metastases (MET). Components of these progressions are initiation, frequency, growth duration, and survival. These characteristics describe principles which proposed molecular concepts and hypotheses must align with.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a population-based retrospective modeling approach using data from the Munich Cancer Registry key steps and factors associated with metastasis were identified and quantified. Analysis of 66.800 patient datasets over four time periods since 1978, reliable evidence is obtained even in small subgroups. Together with results of clinical trials on prevention and adjuvant treatment (AT) principles for the MET process and AT are derived.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median growth periods for PT\/MET\/LR\/pLN comes to 12.5\/8.8\/5\/3.5\u00a0years, respectively. Even if 30% of METs only appear after 10\u00a0years, a pre-diagnosis MET initiation principle not a delayed one should be true. The growth times of PTs and METs vary by a factor of 10 or more but their ratio is robust at about 1.4. Principles of AT are 50% PT eradication, the selective and partial eradication of bone and lung METs. This cannot be improved by extending the duration of the previously known ATs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A paradigm of ten principles for the MET process and ATs is derived from real world data and clinical trials indicates that there is no rationale for the long-term application of endocrine ATs, risk of PTs by hormone replacement therapies, or cascading initiation of METs. The principles show limits and opportunities for innovation also through alternative interpretations of well-known studies. The outlined MET process should be generalizable to all solid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-022-04369-4","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T03:02:40Z","timestamp":1671505360000},"page":"721-735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data"],"prefix":"10.1007","volume":"149","author":[{"given":"Jutta","family":"Engel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Eckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Halfter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Schubert-Fritschle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-0118","authenticated-orcid":false,"given":"Dieter","family":"H\u00f6lzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"issue":"3","key":"4369_CR1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nm.3120","volume":"19","author":"JA Aguirre-Ghiso","year":"2013","unstructured":"Aguirre-Ghiso JA, Bragado P, Sosa MS (2013) Metastasis awakening: targeting dormant cancer. Nat Med 19(3):276\u2013277","journal-title":"Nat Med"},{"issue":"12","key":"4369_CR2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrc4029","volume":"15","author":"PM Altrock","year":"2015","unstructured":"Altrock PM, Liu LL, Michor F (2015) The mathematics of cancer: integrating quantitative models. Nat Rev Cancer 15(12):730\u2013745","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"4369_CR3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11864-020-00788-y","volume":"21","author":"A Anandan","year":"2020","unstructured":"Anandan A, Sharifi M, O\u2019Regan R (2020) Molecular assays to determine optimal duration of adjuvant endocrine therapy in breast cancer. Curr Treat Options Oncol 21(10):84","journal-title":"Curr Treat Options Oncol"},{"issue":"22","key":"4369_CR4","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1200\/JCO.19.00945","volume":"37","author":"F Andre","year":"2019","unstructured":"Andre F, Ismaila N, Henry NL, Somerfield MR, Bast RC, Barlow W et al (2019) Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx. J Clin Oncol: off J Am Soc Clin Oncol 37(22):1956\u20131964","journal-title":"J Clin Oncol: off J Am Soc Clin Oncol"},{"issue":"7757","key":"4369_CR5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","volume":"569","author":"F Bertucci","year":"2019","unstructured":"Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N et al (2019) Genomic characterization of metastatic breast cancers. Nature 569(7757):560\u2013564","journal-title":"Nature"},{"issue":"4","key":"4369_CR6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(14)70069-5","volume":"15","author":"FC Bidard","year":"2014","unstructured":"Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D et al (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15(4):406\u2013414","journal-title":"Lancet Oncol"},{"issue":"7249","key":"4369_CR7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nature08021","volume":"459","author":"PD Bos","year":"2009","unstructured":"Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX et al (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459(7249):1005\u20131009","journal-title":"Nature"},{"key":"4369_CR8","volume-title":"Cancer incidence in five continents, Vol XI (electronic version)","author":"F Bray","year":"2017","unstructured":"Bray F, Colombet M, Mery L, Pineros M, Znaor A, Zanetti R et al (2017) Cancer incidence in five continents, Vol XI (electronic version). IARC Scientific Publication No166, Lyon"},{"key":"4369_CR9","volume-title":"The TNM classification of malignant tumours","year":"2016","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C (eds) (2016) The TNM classification of malignant tumours, 8th edn. Wiley & Sons","edition":"8"},{"issue":"5","key":"4369_CR10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.18.01160","volume":"37","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA et al (2019) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol: off J Am Soc Clin Oncol 37(5):423\u2013438","journal-title":"J Clin Oncol: off J Am Soc Clin Oncol"},{"issue":"1","key":"4369_CR11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41523-021-00269-x","volume":"7","author":"GG Bushnell","year":"2021","unstructured":"Bushnell GG, Deshmukh AP, den Hollander P, Luo M, Soundararajan R, Jia D et al (2021) Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge. NPJ Breast Cancer 7(1):66","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"4369_CR12","first-page":"512","volume":"35","author":"TP Butler","year":"1975","unstructured":"Butler TP, Gullino PM (1975) Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Can Res 35(3):512\u2013516","journal-title":"Can Res"},{"issue":"9","key":"4369_CR13","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/archsurg.1984.01390210063014","volume":"119","author":"B Cady","year":"1984","unstructured":"Cady B (1984) Lymph node metastases. Indicators, but not governors of survival. Arch Surg 119(9):1067\u20131072","journal-title":"Arch Surg"},{"issue":"10075","key":"4369_CR14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E et al (2017) 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet 389(10075):1195\u20131205","journal-title":"Lancet"},{"issue":"9","key":"4369_CR15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/bjs.1800710924","volume":"71","author":"MA Chaudary","year":"1984","unstructured":"Chaudary MA, Millis RR, Hoskins EO, Halder M, Bulbrook RD, Cuzick J et al (1984) Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg 71(9):711\u2013714","journal-title":"Br J Surg"},{"issue":"24","key":"4369_CR16","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","volume":"289","author":"RT Chlebowski","year":"2003","unstructured":"Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women\u2019s health initiative randomized trial. JAMA 289(24):3243\u20133253","journal-title":"JAMA"},{"issue":"6","key":"4369_CR17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1056\/NEJMoa0807684","volume":"360","author":"RT Chlebowski","year":"2009","unstructured":"Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M et al (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360(6):573\u2013587","journal-title":"N Engl J Med"},{"issue":"7","key":"4369_CR18","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1200\/JCO.2005.07.094","volume":"23","author":"M Colleoni","year":"2005","unstructured":"Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Mazzarol G, Pruneri G et al (2005) Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol: off J Am Soc Clin Oncol 23(7):1379\u20131389","journal-title":"J Clin Oncol: off J Am Soc Clin Oncol"},{"issue":"9","key":"4369_CR19","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","volume":"34","author":"M Colleoni","year":"2016","unstructured":"Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thurlimann B et al (2016) Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol: off J Am Soc Clin Oncol 34(9):927\u2013935","journal-title":"J Clin Oncol: off J Am Soc Clin Oncol"},{"key":"4369_CR20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-3-642-28160-0_2","volume":"195","author":"E Comen","year":"2012","unstructured":"Comen E, Norton L (2012) Self-seeding in cancer. Recent Results Cancer Res 195:13\u201323","journal-title":"Recent Results Cancer Res"},{"issue":"12 Suppl 1","key":"4369_CR21","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.amjmed.2010.10.004","volume":"123","author":"J Concato","year":"2010","unstructured":"Concato J, Lawler EV, Lew RA, Gaziano JM, Aslan M, Huang GD (2010) Observational methods in comparative effectiveness research. Am J Med 123(12 Suppl 1):e16-23","journal-title":"Am J Med"},{"key":"4369_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx421.002","author":"P Conte","year":"2018","unstructured":"Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O et al (2018) 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized short-HER study. Ann Oncol: off J Eur Soc Med Oncol\/ESMO. https:\/\/doi.org\/10.1093\/annonc\/mdx421.002","journal-title":"Ann Oncol: off J Eur Soc Med Oncol\/ESMO"},{"issue":"9938","key":"4369_CR23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164\u2013172","journal-title":"Lancet"},{"key":"4369_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-15047-9","volume":"11","author":"GD Cresswell","year":"2020","unstructured":"Cresswell GD, Nichol D, Spiteri I, Tari H, Zapata L, Heide T et al (2020) Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking. Nat Commun 11:1\u201312","journal-title":"Nat Commun"},{"key":"4369_CR25","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.1906.25210220006001a","volume":"47","author":"G Crile","year":"1906","unstructured":"Crile G (1906) Excision of cancer of the head and neck. JAMA 47:1780\u20131786","journal-title":"JAMA"},{"issue":"8","key":"4369_CR26","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781\u2013791","journal-title":"N Engl J Med"},{"issue":"8","key":"4369_CR27","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","volume":"28","author":"G Curigliano","year":"2017","unstructured":"Curigliano G, Burstein HJ, Gnant M, Dubsky P, Loibl S et al (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol: off J Eur Soc Med Oncol\/ESMO 28(8):1700\u20131712","journal-title":"Ann Oncol: off J Eur Soc Med Oncol\/ESMO"},{"issue":"8","key":"4369_CR28","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S1470-2045(17)30536-3","volume":"18","author":"J Cuzick","year":"2017","unstructured":"Cuzick J (2017) Preventive therapy for cancer. Lancet Oncol 18(8):e472\u2013e482","journal-title":"Lancet Oncol"},{"key":"4369_CR29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A et al (2015) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16:67\u201375","journal-title":"Lancet Oncol"},{"key":"4369_CR30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","volume":"395","author":"J Cuzick","year":"2020","unstructured":"Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE et al (2020) Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet 395:117\u2013122","journal-title":"Lancet"},{"key":"4369_CR31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805\u2013816","journal-title":"Lancet"},{"issue":"7","key":"4369_CR32","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa0904832","volume":"361","author":"M de Boer","year":"2009","unstructured":"de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM et al (2009) Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 361(7):653\u2013663","journal-title":"N Engl J Med"},{"issue":"5","key":"4369_CR33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1023\/A:1008321415065","volume":"11","author":"T Delozier","year":"2000","unstructured":"Delozier T, Switsers O, Genot JY, Ollivier JM, Hery M, Namer M et al (2000) Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial). Ann Oncol: off J Eur Soc Med Oncol\/ESMO 11(5):515\u2013519","journal-title":"Ann Oncol: off J Eur Soc Med Oncol\/ESMO"},{"issue":"1","key":"4369_CR34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10555-016-9609-1","volume":"35","author":"C Desmedt","year":"2016","unstructured":"Desmedt C, Yates L, Kulka J (2016) Catalog of genetic progression of human cancers: breast cancer. Cancer Metastasis Rev 35(1):49\u201362","journal-title":"Cancer Metastasis Rev"},{"issue":"8785","key":"4369_CR35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0140-6736(92)90997-H","volume":"339","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1992","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early breast cancer trialists\u2019 collaborative group. Lancet 339(8785):71\u201385","journal-title":"Lancet"},{"issue":"9114","key":"4369_CR36","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early breast cancer trialists\u2019 collaborative group. Lancet 351(9114):1451\u20131467","journal-title":"Lancet"},{"issue":"9503","key":"4369_CR37","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","volume":"366","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087\u20132106","journal-title":"Lancet"},{"key":"4369_CR38","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (2011a) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 378:1707\u20131716","journal-title":"Lancet"},{"issue":"9793","key":"4369_CR39","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (2011b) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771\u2013784","journal-title":"Lancet"},{"issue":"9814","key":"4369_CR40","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2012","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432\u2013444","journal-title":"Lancet"},{"issue":"3","key":"4369_CR41","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","volume":"23","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2022","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (2022) Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol 23(3):382\u2013392","journal-title":"Lancet Oncol"},{"issue":"10","key":"4369_CR42","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2016.69.4406","volume":"35","author":"MJ Ellis","year":"2017","unstructured":"Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ et al (2017) Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American college of surgeons oncology group Z1031 trial (alliance). J Clin Oncol: off J Am Soc Clin Oncol 35(10):1061\u20131069","journal-title":"J Clin Oncol: off J Am Soc Clin Oncol"},{"issue":"3","key":"4369_CR43","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.breast.2005.05.009","volume":"15","author":"J Engel","year":"2006","unstructured":"Engel J, Lebeau A, Sauer H, Holzel D (2006) Are we wasting our time with the sentinel technique? Fifteen reasons to stop axilla dissection. Breast (edinburgh, Scotland) 15(3):452\u2013455","journal-title":"Breast (edinburgh, Scotland)"},{"key":"4369_CR44","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10555-011-9343-7","volume":"31","author":"J Engel","year":"2012","unstructured":"Engel J, Emeny RT, Holzel D (2012) Positive lymph nodes do not metastasize. Cancer Metastasis Rev 31:235\u2013246","journal-title":"Cancer Metastasis Rev"},{"key":"4369_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2019.07.008","volume":"48","author":"J Engel","year":"2019","unstructured":"Engel J, Weichert W, Jung A, Emeny R, H\u00f6lzel D (2019) Lymph node infiltration, parallel metastasis and treatment success in breast cancer. Breast (edinburgh, Scotland) 48:1\u20136","journal-title":"Breast (edinburgh, Scotland)"},{"key":"4369_CR46","first-page":"220","volume":"13","author":"J Engel","year":"2020","unstructured":"Engel J, Schubert-Fritschle G, H\u00f6lzel D (2020) Hormone replacement therapy and elevated breast cancer risk: an artifact of growth acceleration? MEDRXIV 13:220","journal-title":"MEDRXIV"},{"issue":"8","key":"4369_CR47","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00432-020-03264-0","volume":"146","author":"J Engel","year":"2020","unstructured":"Engel J, Schubert-Fritschle G, Emeny R, H\u00f6lzel D (2020b) Breast cancer: are long-term and intermittent endocrine therapies equally effective? J Cancer Res Clin Oncol 146(8):2041\u20132048","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"4369_CR48","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0959-8049(02)00673-1","volume":"39","author":"IS Fentiman","year":"2003","unstructured":"Fentiman IS, Christiaens MR, Paridaens R, Van Geel A, Rutgers E, Berner J et al (2003) Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer (oxford, England: 1990) 39(3):309\u2013316","journal-title":"Eur J Cancer (oxford, England: 1990)"},{"issue":"16","key":"4369_CR49","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa022152","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233\u20131241","journal-title":"N Engl J Med"},{"issue":"22","key":"4369_CR50","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A et al (2005) Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 97(22):1652\u20131662","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"4369_CR51","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.ejca.2014.05.010","volume":"50","author":"DB Fontein","year":"2014","unstructured":"Fontein DB, Charehbili A, Nortier JW, Meershoek-Klein Kranenbarg E, Kroep JR, Putter H et al (2014) Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients\u2013a phase II trial. Eur J Cancer (oxford, England: 1990) 50(13):2190\u20132200","journal-title":"Eur J Cancer (oxford, England: 1990)"},{"issue":"24","key":"4369_CR52","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","volume":"81","author":"MH Gail","year":"1989","unstructured":"Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879\u20131886","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"4369_CR53","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (alliance) randomized clinical trial. JAMA 318(10):918\u2013926","journal-title":"JAMA"},{"issue":"8","key":"4369_CR54","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/annonc\/mdv215","volume":"26","author":"M Gnant","year":"2015","unstructured":"Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E et al (2015) Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann Oncol: off J Eur Soc Med Oncol\/ESMO 26(8):1685\u20131691","journal-title":"Ann Oncol: off J Eur Soc Med Oncol\/ESMO"},{"issue":"9897","key":"4369_CR55","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","volume":"382","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021\u20131028","journal-title":"Lancet"},{"issue":"7547","key":"4369_CR56","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","volume":"520","author":"G Gundem","year":"2015","unstructured":"Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520(7547):353\u2013357","journal-title":"Nature"},{"key":"4369_CR57","first-page":"497","volume":"20","author":"W Halsted","year":"1894","unstructured":"Halsted W (1894) The results of operations for the cure of the cancer of the breast performed at the Johns Hopkins hospital from June 1889 to January 1894. Arch Surg 20:497","journal-title":"Arch Surg"},{"issue":"5","key":"4369_CR58","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"key":"4369_CR59","volume":"371","author":"TP Hanna","year":"2020","unstructured":"Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E et al (2020) Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ (clinical Research Ed) 371:m4087","journal-title":"BMJ (clinical Research Ed)"},{"issue":"34","key":"4369_CR60","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1200\/JCO.2012.41.6701","volume":"30","author":"DL Hershman","year":"2012","unstructured":"Hershman DL, Wright JD (2012) Comparative effectiveness research in oncology methodology: observational data. J Clin Oncol: off J Am Soc Clin Oncol 30(34):4215\u20134222","journal-title":"J Clin Oncol: off J Am Soc Clin Oncol"},{"issue":"10","key":"4369_CR61","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13(10):714\u2013726","journal-title":"Nat Rev Cancer"},{"key":"4369_CR62","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10555-010-9260-1","volume":"29","author":"D H\u00f6lzel","year":"2010","unstructured":"H\u00f6lzel D, Eckel R, Emeny R, Engel J (2010) Distant metastases do not metastasize. Cancer Metastasis Rev 29:737\u2013750","journal-title":"Cancer Metastasis Rev"},{"key":"4369_CR63","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00432-017-2428-0","volume":"143","author":"D H\u00f6lzel","year":"2017","unstructured":"H\u00f6lzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M et al (2017a) Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich cancer registry. J Cancer Res Clin Oncol 143:1701\u20131712","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"4369_CR64","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00432-016-2306-1","volume":"143","author":"D H\u00f6lzel","year":"2017","unstructured":"H\u00f6lzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M et al (2017b) Survival of de novo stage IV breast cancer patients over three decades. J Cancer Res Clin Oncol 143(3):509\u2013519","journal-title":"J Cancer Res Clin Oncol"},{"key":"4369_CR65","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41523-017-0014-x","volume":"3","author":"N Houssami","year":"2017","unstructured":"Houssami N, Hunter K (2017) The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening. NPJ Breast Cancer 3:12","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"4369_CR66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrc.2017.126","volume":"18","author":"KW Hunter","year":"2018","unstructured":"Hunter KW, Amin R, Deasy S, Ha NH, Wakefield L (2018) Genetic insights into the morass of metastatic heterogeneity. Nat Rev Cancer 18(4):211\u2013223","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4369_CR67","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2007.12.003","volume":"13","author":"Y Husemann","year":"2008","unstructured":"Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E et al (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13(1):58\u201368","journal-title":"Cancer Cell"},{"issue":"9","key":"4369_CR68","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1158\/1078-0432.CCR-10-2515","volume":"17","author":"W Janni","year":"2011","unstructured":"Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Juckstock J et al (2011) Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse\u2013a European pooled analysis. Clin Cancer Res: off J Am Assoc Cancer Res 17(9):2967\u20132976","journal-title":"Clin Cancer Res: off J Am Assoc Cancer Res"},{"issue":"10","key":"4369_CR69","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","volume":"12","author":"R Jeselsohn","year":"2015","unstructured":"Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R (2015) ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol 12(10):573\u2013583","journal-title":"Nat Rev Clin Oncol"},{"key":"4369_CR70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.breast.2020.01.006","volume":"50","author":"P Jurrius","year":"2020","unstructured":"Jurrius P, Green T, Garmo H, Young M, Cariati M, Gillett C et al (2020) Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup - the \u201cATRESS\u201d phenomenon. Breast (edinburgh, Scotland) 50:39\u201348","journal-title":"Breast (edinburgh, Scotland)"},{"issue":"10","key":"4369_CR71","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","volume":"19","author":"L Keller","year":"2019","unstructured":"Keller L, Pantel K (2019) Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer 19(10):553\u2013567","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"4369_CR72","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","volume":"139","author":"MY Kim","year":"2009","unstructured":"Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L et al (2009) Tumor self-seeding by circulating cancer cells. Cell 139(7):1315\u20131326","journal-title":"Cell"},{"key":"4369_CR73","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.humpath.2018.04.016","volume":"78","author":"H Kim","year":"2018","unstructured":"Kim H, Kim CY, Park KH, Kim A (2018) Clonality analysis of multifocal ipsilateral breast carcinomas using X-chromosome inactivation patterns. Hum Pathol 78:106\u2013114","journal-title":"Hum Pathol"},{"issue":"4","key":"4369_CR74","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","volume":"168","author":"AW Lambert","year":"2017","unstructured":"Lambert AW, Pattabiraman DR, Weinberg RA (2017) Emerging biological principles of metastasis. Cell 168(4):670\u2013691","journal-title":"Cell"},{"key":"4369_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31451-4","author":"EP Mamounas","year":"2017","unstructured":"Mamounas EP, Kuehn T, Rutgers EJT, von Minckwitz G (2017) Current approach of the axilla in patients with early-stage breast cancer. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(17)31451-4","journal-title":"Lancet"},{"issue":"20","key":"4369_CR76","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.19.02905","volume":"38","author":"EP Mamounas","year":"2020","unstructured":"Mamounas EP, Mitchell MP, Woodward WA (2020) Molecular predictive and prognostic markers in locoregional management. J Clin Oncol: off J Am Soc Clin Oncol 38(20):2310\u20132320","journal-title":"J Clin Oncol: off J Am Soc Clin Oncol"},{"issue":"8","key":"4369_CR77","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1245\/s10434-017-5866-7","volume":"24","author":"A Mamtani","year":"2017","unstructured":"Mamtani A, Patil S, Stempel M, Morrow M (2017) Axillary micrometastases and isolated tumor cells are not an indication for post-mastectomy radiotherapy in stage 1 and 2 breast cancer. Ann Surg Oncol 24(8):2182\u20132188","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4369_CR78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/COC.0b013e31819cccc3","volume":"33","author":"S McGrath","year":"2010","unstructured":"McGrath S, Antonucci J, Goldstein N, Wallace M, Mitchell C, Grills I et al (2010) Long-term patterns of in-breast failure in patients with early stage breast cancer treated with breast-conserving therapy: a molecular based clonality evaluation. Am J Clin Oncol 33(1):17\u201322","journal-title":"Am J Clin Oncol"},{"issue":"24","key":"4369_CR79","doi-asserted-by":"crossref","first-page":"8152","DOI":"10.1158\/1078-0432.CCR-04-1110","volume":"10","author":"S Meng","year":"2004","unstructured":"Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF et al (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res: off J Am Assoc Cancer Res 10(24):8152\u20138162","journal-title":"Clin Cancer Res: off J Am Assoc Cancer Res"},{"issue":"5","key":"4369_CR80","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3390\/ijms21051696","volume":"21","author":"ME Menyailo","year":"2020","unstructured":"Menyailo ME, Tretyakova MS, Denisov EV (2020) Heterogeneity of circulating tumor cells in breast cancer: identifying metastatic seeds. Int J Mol Sci 21(5):1696","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4369_CR81","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","volume":"6","author":"AI Minchinton","year":"2006","unstructured":"Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6(8):583\u2013592","journal-title":"Nat Rev Cancer"},{"key":"4369_CR82","unstructured":"Munich Cancer Registry. http:\/\/www.tumorregister-muenchen.de\/en\/. Accessed 10 Nov 2021"},{"issue":"9","key":"4369_CR83","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrc2713","volume":"9","author":"EA Musgrove","year":"2009","unstructured":"Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631\u2013643","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4369_CR84","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10549-017-4644-3","volume":"169","author":"SA Narod","year":"2018","unstructured":"Narod SA, Sopik V (2018) Is invasion a necessary step for metastases in breast cancer? Breast Cancer Res Treat 169(1):9\u201323","journal-title":"Breast Cancer Res Treat"},{"key":"4369_CR85","unstructured":"Noone A, Howlader N, Krapcho M, Miller D, Brest Ae. SEER Cancer Statistics Review (1975\u20132017) National Cancer Institute. Bethesda, MD. http:\/\/seer.cancer.gov\/. Accessed 10 Nov 2021"},{"issue":"2","key":"4369_CR86","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jamcollsurg.2006.11.005","volume":"204","author":"BJ O'Daly","year":"2007","unstructured":"O\u2019Daly BJ, Sweeney KJ, Ridgway PF, Quinn C, McDermott EW, O\u2019Higgins NJ et al (2007) The accuracy of combined versus largest diameter in staging multifocal breast cancer. J Am Coll Surg 204(2):282\u2013285","journal-title":"J Am Coll Surg"},{"issue":"3","key":"4369_CR87","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.stem.2014.02.002","volume":"14","author":"T Oskarsson","year":"2014","unstructured":"Oskarsson T, Batlle E, Massague J (2014) Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 14(3):306\u2013321","journal-title":"Cell Stem Cell"},{"issue":"19","key":"4369_CR88","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P et al (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836\u20131846","journal-title":"N Engl J Med"},{"issue":"2","key":"4369_CR89","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijrobp.2010.05.063","volume":"81","author":"V Panet-Raymond","year":"2011","unstructured":"Panet-Raymond V, Truong PT, McDonald RE, Alexander C, Ross L, Ryhorchuk A et al (2011) True recurrence versus new primary: an analysis of ipsilateral breast tumor recurrences after breast-conserving therapy. Int J Radiat Oncol Biol Phys 81(2):409\u2013417","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"4369_CR90","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16","author":"K Pantel","year":"2019","unstructured":"Pantel K, Alix-Panabi\u00e8res C (2019) Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol 16(7):409\u2013424","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"4369_CR91","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.breast.2003.11.004","volume":"13","author":"L Pedersen","year":"2004","unstructured":"Pedersen L, Gunnarsdottir KA, Rasmussen BB, Moeller S, Lanng C (2004) The prognostic influence of multifocality in breast cancer patients. Breast (edinburgh, Scotland) 13(3):188\u2013193","journal-title":"Breast (edinburgh, Scotland)"},{"issue":"5","key":"4369_CR92","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc.2017.6","volume":"17","author":"H Peinado","year":"2017","unstructured":"Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G et al (2017) Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer 17(5):302\u2013317","journal-title":"Nat Rev Cancer"},{"issue":"6382","key":"4369_CR93","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1126\/science.aal3622","volume":"359","author":"ER Pereira","year":"2018","unstructured":"Pereira ER, Kedrin D, Seano G, Gautier O, Meijer EFJ, Jones D et al (2018) Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science (new York, NY) 359(6382):1403\u20131407","journal-title":"Science (new York, NY)"},{"issue":"24","key":"4369_CR94","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/jnci\/88.24.1791","volume":"88","author":"R Peto","year":"1996","unstructured":"Peto R (1996) Five years of tamoxifen\u2013or more? J Natl Cancer Inst 88(24):1791\u20131793","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4369_CR95","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.annonc.2020.10.477","volume":"32","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Rulli E, Labianca R, Lonardi S, Rosati G, Dotti K et al (2020) Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomized trial. Ann Oncol: off J Eur Soc Med Oncol\/ESMO 32(1):66\u201376","journal-title":"Ann Oncol: off J Eur Soc Med Oncol\/ESMO"},{"issue":"8","key":"4369_CR96","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1470-2045(13)70225-0","volume":"14","author":"X Pivot","year":"2013","unstructured":"Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T et al (2013) 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 14(8):741\u2013748","journal-title":"Lancet Oncol"},{"issue":"1","key":"4369_CR97","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ng1060","volume":"33","author":"S Ramaswamy","year":"2003","unstructured":"Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33(1):49\u201354","journal-title":"Nat Genet"},{"issue":"3","key":"4369_CR98","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N et al (2018) The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34(3):427\u201338.e6","journal-title":"Cancer Cell"},{"issue":"12","key":"4369_CR99","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S1470-2045(13)70411-X","volume":"14","author":"A Robidoux","year":"2013","unstructured":"Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN et al (2013) Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 14(12):1183\u20131192","journal-title":"Lancet Oncol"},{"issue":"5","key":"4369_CR100","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0360-3016(00)01378-X","volume":"48","author":"TE Smith","year":"2000","unstructured":"Smith TE, Lee D, Turner BC, Carter D, Haffty BG (2000) True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys 48(5):1281\u20131289","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4369_CR101","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.14694\/EdBook_AM.2014.34.e16","volume":"2014","author":"IE Smith","year":"2014","unstructured":"Smith IE, Yeo B, Schiavon G (2014) The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough? Am Soc Clin Oncol Educ Book 2014:e16\u2013e24","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"4369_CR102","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/1097-0142(19930315)71:6<2013::AID-CNCR2820710615>3.0.CO;2-V","volume":"71","author":"JA Spratt","year":"1993","unstructured":"Spratt JA, von Fournier D, Spratt JS, Weber EE (1993) Decelerating growth and human breast cancer. Cancer 71(6):2013\u20132019","journal-title":"Cancer"},{"issue":"11","key":"4369_CR103","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","volume":"2","author":"LM Spring","year":"2016","unstructured":"Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ et al (2016) Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol 2(11):1477\u20131486","journal-title":"JAMA Oncol"},{"issue":"6282","key":"4369_CR104","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1126\/science.aaf2784","volume":"352","author":"S Turajlic","year":"2016","unstructured":"Turajlic S, Swanton C (2016) Metastasis as an evolutionary process. Science (new York, NY) 352(6282):169\u2013175","journal-title":"Science (new York, NY)"},{"issue":"4","key":"4369_CR105","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1172\/JCI96149","volume":"128","author":"I Ullah","year":"2018","unstructured":"Ullah I, Karthik GM, Alkodsi A, Kjallquist U, Stalhammar G, Lovrot J et al (2018) Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes. J Clin Investig 128(4):1355\u20131370","journal-title":"J Clin Investig"},{"issue":"2","key":"4369_CR106","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","volume":"147","author":"S Valastyan","year":"2011","unstructured":"Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147(2):275\u2013292","journal-title":"Cell"},{"issue":"2","key":"4369_CR107","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10549-017-4428-9","volume":"166","author":"LJ van\u2019t Veer","year":"2017","unstructured":"van\u2019t Veer LJ, Yau C, Yu NY, Benz CC, Nordenskj\u00f6ld B, Fornander T et al (2017) Tamoxifen therapy benefit for patients with 70-gene signature high and low risk. Breast Cancer Res Treat 166(2):593\u2013601","journal-title":"Breast Cancer Res Treat"},{"key":"4369_CR108","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1471-2407-10-205","volume":"10","author":"A Veronesi","year":"2010","unstructured":"Veronesi A, Miolo G, Magri MD, Crivellari D, Scalone S, Bidoli E et al (2010) Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study. BMC Cancer 10:205","journal-title":"BMC Cancer"},{"issue":"5","key":"4369_CR109","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/annonc\/mdx053","volume":"28","author":"A Vivot","year":"2017","unstructured":"Vivot A, Jacot J, Zeitoun JD, Ravaud P, Crequit P, Porcher R (2017) Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000\u20132015. Ann Oncol: off J Eur Soc Med Oncol\/ESMO 28(5):1111\u20131116","journal-title":"Ann Oncol: off J Eur Soc Med Oncol\/ESMO"},{"issue":"15","key":"4369_CR110","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol: off J Am Soc Clin Oncol 30(15):1796\u20131804","journal-title":"J Clin Oncol: off J Am Soc Clin Oncol"},{"issue":"6","key":"4369_CR111","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1055\/a-1111-8734","volume":"80","author":"VP Walter","year":"2020","unstructured":"Walter VP, Taran FA, Wallwiener M, Bauer A, Grischke EM, Walter CB et al (2020) Distribution of the 21-gene breast recurrence score in patients with primary breast cancer in Germany. Geburtshilfe Frauenheilkd 80(6):619\u2013627","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"3","key":"4369_CR112","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/bcr2092","volume":"10","author":"H Weedon-Fekjaer","year":"2008","unstructured":"Weedon-Fekjaer H, Lindqvist BH, Vatten LJ, Aalen OO, Tretli S (2008) Breast cancer tumor growth estimated through mammography screening data. Breast Cancer Res: BCR 10(3):R41","journal-title":"Breast Cancer Res: BCR"},{"issue":"3","key":"4369_CR113","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00132751","volume":"10","author":"L Weiss","year":"1992","unstructured":"Weiss L (1992) Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clin Exp Metas 10(3):191\u2013199","journal-title":"Clin Exp Metas"},{"issue":"15","key":"4369_CR114","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1600249","volume":"375","author":"HG Welch","year":"2016","unstructured":"Welch HG, Prorok PC, O\u2019Malley AJ, Kramer BS (2016) Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med 375(15):1438\u20131447","journal-title":"N Engl J Med"},{"key":"4369_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.02.001","author":"S Werner","year":"2021","unstructured":"Werner S, Heidrich I, Pantel K (2021) Clinical management and biology of tumor dormancy in breast cancer. Sem Cancer Biol. https:\/\/doi.org\/10.1016\/j.semcancer.2021.02.001","journal-title":"Sem Cancer Biol"},{"issue":"4","key":"4369_CR116","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.ijrobp.2009.03.026","volume":"76","author":"E Whipp","year":"2010","unstructured":"Whipp E, Beresford M, Sawyer E, Halliwell M (2010) True local recurrence rate in the conserved breast after magnetic resonance imaging-targeted radiotherapy. Int J Radiat Oncol Biol Phys 76(4):984\u2013990","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7319","key":"4369_CR117","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/nature09515","volume":"467","author":"S Yachida","year":"2010","unstructured":"Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B et al (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114\u20131117","journal-title":"Nature"},{"issue":"2","key":"4369_CR118","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccell.2017.07.005","volume":"32","author":"LR Yates","year":"2017","unstructured":"Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Martincorena I et al (2017) Genomic evolution of breast cancer metastasis and relapse. Cancer Cell 32(2):169\u201384.e7","journal-title":"Cancer Cell"},{"issue":"5","key":"4369_CR119","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2013.07.036","volume":"154","author":"XH Zhang","year":"2013","unstructured":"Zhang XH, Jin X, Malladi S, Zou Y, Wen YH, Brogi E et al (2013) Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell 154(5):1060\u20131073","journal-title":"Cell"},{"key":"4369_CR120","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.12659\/MSM.901566","volume":"23","author":"S Zhang","year":"2017","unstructured":"Zhang S, Ding Y, Zhou Q, Wang C, Wu P, Dong J (2017) Correlation factors analysis of breast cancer tumor volume doubling time measured by 3D-ultrasound. Med Sci Monit: Int Med J Exp Clin Res 23:3147\u20133153","journal-title":"Med Sci Monit: Int Med J Exp Clin Res"},{"issue":"2","key":"4369_CR121","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10549-020-05557-x","volume":"180","author":"L Zhang","year":"2020","unstructured":"Zhang L, Hsieh MC, Petkov V, Yu Q, Chiu YW, Wu XC (2020) Trend and survival benefit of oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004\u20132015. Breast Cancer Res Treat 180(2):491\u2013501","journal-title":"Breast Cancer Res Treat"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04369-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04369-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04369-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T02:13:58Z","timestamp":1676600038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04369-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["4369"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04369-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.12.01.20214551","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"assertion":[{"value":"13 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}